The authors, for the first time, observed that the levels of accepted markers of platelet activation, PMPs and CD62, were, respectively, over twofold and 1.7-fold higher in patients with RR MS in comparison to healthy controls [21]. This evidence concerns the gene SELP and myeloid sarcoma.